MetaCap

Processa Pharmaceuticals (PCSA) vs Pulmatrix (PULM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pulmatrix is the larger company by market cap ($4.6 million vs $4.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PCSA+9.86%PULM-14.77%
+40%+11%-17%
Oct 7, 20261 yearNov 20, 2026
PCSA+2.63%PULM-13.01%
+29%+7%-15%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PCSA versus PULM key metrics
MetricPCSAPULM
Share price$1.56$1.27
Market cap$4.37M$4.64M
1-day change-7.69%-10.56%
EPS (TTM)$-68.29$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-13.56M$-5.16M
52-week high$8.88$4.94
52-week low$1.04$1.06
Distance from 52-week high-82.43%-74.29%
Average volume79.50K35.45K
Shares outstanding2.80M3.65M
Employees122
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Processa Pharmaceuticals

PCSA stock →

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Pulmatrix

PULM stock →

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

PCSA vs PULM FAQ

Which is bigger, Processa Pharmaceuticals or Pulmatrix?

Pulmatrix (PULM) is larger, with a market capitalization of $4.64M compared with $4.37M for Processa Pharmaceuticals (PCSA).

Are Processa Pharmaceuticals and Pulmatrix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons